Mercury Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 287757, "name": "Mercury Labs", "stock_name": "Mercury Labs", "full_name": "Mercury Laboratories Ltd", "name_url": "stocks-analysis/mercury-labs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "740.85", "chg": -36.7, "chgp": "-4.72%", "dir": -1, "prev_price": "777.55", "mcapval": "99.00 Cr", "mcap": "Micro Cap", "scripcode": 538964, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE947G01011", "curr_date": "Jun 10, 03:30 PM", "curr_time": "03:52 AM", "last_traded_at": "Jun 10, 03:30 PM IST", "bse_nse_vol": "75 ", "exc_status": "Active", "traded_date": "Jun 10, 2026", "traded_date_str": "2026 06 10", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mercury-labs-287757-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Mercury Laboratories Ltd Reports Flat Quarterly Performance Amid Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-reports-flat-quarterly-performance-amid-margin-pressures-4024912", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/MercuryLaborato_fintrenddot_4024912.png", "date": "2026-06-01 08:00:18", "description": "Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite a higher profit after tax (PAT) for the nine-month period, the company’s quarterly operating profit and margins have contracted sharply, prompting a downgrade in its Mojo Grade to Strong Sell." }, { "title": "Mercury Laboratories Ltd Gains 3.13%: 3 Key Factors Driving the Week’s Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-gains-313-3-key-factors-driving-the-weeks-volatility-4024459", "imagepath": "", "date": "2026-05-31 11:00:09", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 25:</strong> Stock rallies 19.99% on upgrade to Sell rating</p>\n <p><strong>May 26:</strong> Valuation shifts to fair amid strong price rally</p>\n <p><strong>May 27:</strong> Downgrade to Strong Sell triggers 6.25% decline</p>\n <p><strong>May 29:</strong> Week closes at Rs.763.45, up 3.13% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.740.25</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.763.45</div><div c..." }, { "title": "Are Mercury Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-mercury-laboratories-ltd-latest-results-good-or-bad-4023833", "imagepath": "", "date": "2026-05-30 19:46:27", "description": "Mercury Laboratories Ltd's latest financial results for the quarter ended March 2026 reveal a complex operational landscape characterized by both revenue growth and profitability challenges. The company reported net sales of ₹20.44 crores, reflecting an 11.39% increase compared to the previous quarter, which contrasts with a slight year-on-year decline of 1.06%. This sequential growth in sales indicates some positive momentum; however, it is overshadowed by a significant contraction in profitability.\n\nNet profit for the same quarter was recorded at ₹1.23 crores, which shows a 23% increase from the previous quarter, yet this figure also represents a year-on-year decrease of 1.06%. The operating margin, a critical indicator of operational efficiency, fell to 9.93%, marking a notable decline from 13.73% in the preceding quarter and indicating pressures on cost management and pricing strategies.\n\nThe operationa..." }, { "title": "Mercury Laboratories Q4 FY26: Profitability Concerns Deepen as Margins Contract Sharply", "link": "https://www.marketsmojo.com/news/result-analysis/mercury-laboratories-q4-fy26-profitability-concerns-deepen-as-margins-contract-sharply-4022628", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MercuryLaborato_quaterlyResult_4022628.png", "date": "2026-05-29 20:47:12", "description": "Mercury Laboratories Ltd., a Mumbai-based pharmaceutical company, reported concerning results for Q4 FY26 (January-March 2026), with net profit rising 10.81% quarter-on-quarter to ₹1.23 crores but declining 1.06% year-on-year from ₹1.11 crores. The ₹93.00 crore market capitalisation company faced significant margin pressures as operating profitability deteriorated to its lowest level in recent quarters, raising questions about the sustainability of its business model in an increasingly competitive pharmaceutical landscape." }, { "title": "Mercury Laboratories Ltd Downgraded to Strong Sell Amid Technical Weakness and Mixed Fundamentals", "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-downgraded-to-strong-sell-amid-technical-weakness-and-mixed-fundamentals-4017750", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MercuryLaborato_mojoScore_4017750.png", "date": "2026-05-28 08:16:13", "description": "Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 27 May 2026. This shift reflects deteriorating technical indicators, subdued financial trends, and a cautious outlook on quality metrics despite an attractive valuation profile. The downgrade underscores growing concerns over the company’s long-term fundamentals and market performance relative to peers and benchmarks." }, { "title": "Mercury Laboratories Ltd: Valuation Shifts Signal Changing Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-valuation-shifts-signal-changing-price-attractiveness-4012365", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MercuryLaborato_valuationdot_4012365.png", "date": "2026-05-26 08:00:34", "description": "Mercury Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating as its share price surged nearly 20% in a single day. Despite this rally, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now align more closely with industry peers, signalling a recalibration of price attractiveness in the Pharmaceuticals & Biotechnology sector." }, { "title": "Mercury Laboratories Ltd Upgraded to Sell on Technical Improvements and Valuation Appeal", "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-upgraded-to-sell-on-technical-improvements-and-valuation-appeal-4010080", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MercuryLaborato_mojoScore_4010080.png", "date": "2026-05-25 08:11:17", "description": "Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 22 May 2026. This change reflects a nuanced shift in the company’s technical outlook amid ongoing challenges in its fundamental and valuation metrics. While the technical indicators have improved modestly, the company continues to face headwinds in long-term financial trends and relative market performance." }, { "title": "Mercury Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-is-rated-sell-4009180", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MercuryLaborato_mojoScore_4009180.png", "date": "2026-05-24 10:10:37", "description": "Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with an up-to-date view of the company’s standing." }, { "title": "Mercury Laboratories Ltd Downgraded to Strong Sell Amid Bearish Technicals and Weak Fundamentals", "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-downgraded-to-strong-sell-amid-bearish-technicals-and-weak-fundamentals-3988844", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MercuryLaborato_mojoScore_3988844.png", "date": "2026-05-13 08:19:14", "description": "Mercury Laboratories Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 12 May 2026, reflecting deteriorating technical indicators and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s overall outlook has weakened due to bearish technical trends, subdued long-term financial growth, and valuation concerns within the pharmaceuticals sector." } ], "total": 140, "sid": "287757", "stock_news_url": "https://www.marketsmojo.com/news/mercury-laboratories-287757" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "31-May-2026", "details": "Newspaper publication of audited financial statement for the quarter and year ended on 31.03.2026 is attached", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Change in Management", "datetime": "29-May-2026", "details": "Details of Appointment of Internal Auditor and Cost auditor is attached", "source": "BSE" }, { "caption": "Board Meeting Outcome for Outocme Of Board Meeting Held On May 29 2025", "datetime": "29-May-2026", "details": "Outocme of Board Meeting held on May 29 2025 is attached", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Mercury Laboratories Ltd has declared <strong>35%</strong> dividend, ex-date: 06 Aug 25", "dt": "2025-08-06", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

May 25: Stock rallies 19.99% on upgrade to Sell rating

May 26: Valuation shifts to fair amid strong price rally

May 27: Downgrade to Strong Sell triggers 6.25% decline

May 29: Week closes at Rs.763.45, up 3.13% for the week

Read full news article

Are Mercury Laboratories Ltd latest results good or bad?

2026-05-30 19:46:27

Mercury Laboratories Ltd's latest financial results for the quarter ended March 2026 reveal a complex operational landscape characterized by both revenue growth and profitability challenges. The company reported net sales of ₹20.44 crores, reflecting an 11.39% increase compared to the previous quarter, which contrasts with a slight year-on-year decline of 1.06%. This sequential growth in sales indicates some positive momentum; however, it is overshadowed by a significant contraction in profitability. Net profit for the same quarter was recorded at ₹1.23 crores, which shows a 23% increase from the previous quarter, yet this figure also represents a year-on-year decrease of 1.06%. The operating margin, a critical indicator of operational efficiency, fell to 9.93%, marking a notable decline from 13.73% in the preceding quarter and indicating pressures on cost management and pricing strategies. The operationa...

Read full news article

Mercury Laboratories Q4 FY26: Profitability Concerns Deepen as Margins Contract Sharply

2026-05-29 20:47:12

Mercury Laboratories Ltd., a Mumbai-based pharmaceutical company, reported concerning results for Q4 FY26 (January-March 2026), with net profit rising 10.81% quarter-on-quarter to ₹1.23 crores but declining 1.06% year-on-year from ₹1.11 crores. The ₹93.00 crore market capitalisation company faced significant margin pressures as operating profitability deteriorated to its lowest level in recent quarters, raising questions about the sustainability of its business model in an increasingly competitive pharmaceutical landscape.

Read full news article

Mercury Laboratories Ltd Downgraded to Strong Sell Amid Technical Weakness and Mixed Fundamentals

2026-05-28 08:16:13

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 27 May 2026. This shift reflects deteriorating technical indicators, subdued financial trends, and a cautious outlook on quality metrics despite an attractive valuation profile. The downgrade underscores growing concerns over the company’s long-term fundamentals and market performance relative to peers and benchmarks.

Read full news article

Mercury Laboratories Ltd: Valuation Shifts Signal Changing Price Attractiveness

2026-05-26 08:00:34

Mercury Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating as its share price surged nearly 20% in a single day. Despite this rally, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now align more closely with industry peers, signalling a recalibration of price attractiveness in the Pharmaceuticals & Biotechnology sector.

Read full news article

Mercury Laboratories Ltd Upgraded to Sell on Technical Improvements and Valuation Appeal

2026-05-25 08:11:17

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 22 May 2026. This change reflects a nuanced shift in the company’s technical outlook amid ongoing challenges in its fundamental and valuation metrics. While the technical indicators have improved modestly, the company continues to face headwinds in long-term financial trends and relative market performance.

Read full news article

Mercury Laboratories Ltd is Rated Sell

2026-05-24 10:10:37

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with an up-to-date view of the company’s standing.

Read full news article

Mercury Laboratories Ltd Downgraded to Strong Sell Amid Bearish Technicals and Weak Fundamentals

2026-05-13 08:19:14

Mercury Laboratories Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 12 May 2026, reflecting deteriorating technical indicators and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s overall outlook has weakened due to bearish technical trends, subdued long-term financial growth, and valuation concerns within the pharmaceuticals sector.

Read full news article